Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diosmin plus cabergoline for prevention of ovarian hyperstimulation syndrome in high-risk women undergoing ICSI
ACTRN12614000535673Phase 3Recruiting
- Sponsor
- khalid abd aziz mohamed
- Start
- Feb 2014
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of diosmin and cabergoline in ovarian hyperstimulation syndrome (OHSS), sponsored by khalid abd aziz mohamed. Primary endpoints: Occurrence of ovarian hyperstimulation syndrome, Grade of ovarian hyperstimulation syndrome and 3 more. Started Feb 2014; status: recruiting.
02
Drugs
diosmincabergoline
03
Conditions
ovarian hyperstimulation syndrome (OHSS)
Beyond the preview
Go deeper on ACTRN12614000535673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000535673.